Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06209619 · ClinicalTrials.gov registry record · Phase 1
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
A Phase 1 study of Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and Primary Mediastinal Large B-Cell Lymphoma Recurrent, sponsored by Nathan Denlinger.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06209619 is a Phase 1 study of Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and Primary Mediastinal Large B-Cell Lymphoma Recurrent that is actively recruiting participants, run by Nathan Denlinger. The registered enrollment target is 18 participants, below the 132-participant average among 4 other Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06209619, a Phase 1 study of Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and Primary Mediastinal Large B-Cell Lymphoma Recurrent, is actively recruiting participants, sponsored by Nathan Denlinger.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving CC-99282 with rituximab may be a safe and effective treatment option for patients who have received CAR-T cell therapy for relapsed or refractory non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- PROCEDURE Positron Emission Tomography
- DRUG Golcadomide
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06209619
The ClinicalTrials.gov registry entry for NCT06209619 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 4 other Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent trials with a reported enrollment target (86% lower). The listed sponsor is Nathan Denlinger, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06209619 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06209619 about?
NCT06209619 is a clinical study titled "CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma". This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherap...
What is the current status of trial NCT06209619?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-01-29. Estimated completion is 2026-12-31.
What conditions does trial NCT06209619 study?
This clinical trial studies the following conditions: Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Diffuse Large B-Cell Lymphoma-Refractory, B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent.
What interventions are being tested in trial NCT06209619?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Golcadomide (DRUG).
Who is sponsoring clinical trial NCT06209619?
This trial is sponsored by Nathan Denlinger, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06209619 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
RECRUITING · Phase 1
-
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
RECRUITING · Phase 2
-
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent
All registered trials for this condition
Primary Mediastinal Large B-Cell Lymphoma Recurrent
All registered trials for this condition
Ohio
All trials with a study site in Ohio
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.